trial

Regulation of Arginine-vasopressin (AVP)

NCTId NCT02626832
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 25 (actual)
Sponsored by Yale University
Primary completion 2013-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
25 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2010-02
Primary completion
2013-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Procedural

Sponsors

Yale UniversityLead Sponsor
VA Connecticut Healthcare SystemCollaborator
The John B. Pierce LaboratoryCollaborator

Investigators

1
Handan Gunduz-Bruce, MD, MBAPrincipal Investigator

Sites

2 total
New Haven, United StatesWest Haven, United States

Facts & assertions

4 sourced
Enrollment
25
Phase
NA
Primary Completion Date
2013-11
Status
COMPLETED
relationships
The graph out of here
drug
Procedural
drug
lead_sponsor
Yale University
company
collaborator
VA Connecticut Healthcare System
company
The John B. Pierce Laboratory
company
indication
Depression
indication
Diabetes Insipidus
indication
Schizophrenia
indication
investigator
Handan Gunduz-Bruce, MD, MBA
person